PLoS Genetics · 2013 · 90 citations · 63 references
Life SciencesMolecular BiologyOncologyCancer GeneticsDrug DiscoveryMolecular OncologyCancer Cell SignalingCancer Genomic InstabilityOncogene MutationsSynthetic LethalitySynthetic Lethality In CancerTumor Suppressor GenesAnticancer ActivityCancer Signaling PathwaysChromosome InstabilityFluorescence-based AssaysFluorescence-based ScreeningOncogenic Signaling NetworksTumor Synthetic Lethality NetworksYeast Genetic Screens
Harnessing genetic differences between cancerous and noncancerous cells offers a strategy for the development of new therapies. Extrapolating from yeast genetic interaction data, we used cultured human cells and siRNA to construct and evaluate a synthetic lethal interaction network comprised of chromosome instability (CIN) genes that are frequently mutated in colorectal cancer. A small number of genes in this network were found to have synthetic lethal interactions with a large number of cancer CIN genes; these genes are thus attractive targets for anticancer therapeutic development. The protein product of one highly connected gene, the flap endonuclease FEN1, was used as a target for small-molecule inhibitor screening using a newly developed fluorescence-based assay for enzyme activity. Thirteen initial hits identified through in vitro biochemical screening were tested in cells, and it was found that two compounds could selectively inhibit the proliferation of cultured cancer cells carrying inactivating mutations in CDC4, a gene frequently mutated in a variety of cancers. Inhibition of flap endonuclease activity was also found to recapitulate a genetic interaction between FEN1 and MRE11A, another gene frequently mutated in colorectal cancers, and to lead to increased endogenous DNA damage. These chemical-genetic interactions in mammalian cells validate evolutionarily conserved synthetic lethal interactions and demonstrate that a cross-species candidate gene approach is successful in identifying small-molecule inhibitors that prove effective in a cell-based cancer model.
63
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
Yuri Lazebnik, Scott H. Kaufmann, Serge Desnoyers et al. · Nature · 1994 · 2.6K citations
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn et al. · Nature · 2012 · 2.6K citations · Full text
Medicine, Cancer Biology, Oncology +16